L3VLUP
ProSign in

RGNX · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RGNXAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RGNX
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterRGNXAMGN
Q3 20203 holders, $17m16 holders, $16.3bn
Q4 20203 holders, $6.0m19 holders, $14.0bn
Q1 20212 holders, $33m16 holders, $14.5bn
Q2 20211 holders, $2.0m23 holders, $13.8bn
Q3 2021none listed holders, n.a.24 holders, $11.6bn
Q4 2021none listed holders, n.a.21 holders, $10.4bn
Q1 20222 holders, $17m23 holders, $9.9bn
Q2 20223 holders, $15m28 holders, $9.7bn
Q3 20222 holders, $998k21 holders, $7.9bn
Q4 20223 holders, $13m24 holders, $9.3bn
Q1 20232 holders, $5.8m22 holders, $8.4bn
Q2 20231 holders, $9.8m26 holders, $7.4bn
Q3 20232 holders, $10m26 holders, $8.7bn
Q4 20231 holders, $1.6m24 holders, $8.4bn
Q1 20244 holders, $6.8m25 holders, $6.7bn
Q2 20243 holders, $3.2m20 holders, $8.0bn
Q3 20242 holders, $2.1m21 holders, $8.8bn
Q4 20242 holders, $1.3m20 holders, $8.2bn
Q1 20252 holders, $1.4m25 holders, $12.0bn
Q2 20251 holders, $1.2m20 holders, $10.2bn
Q3 20251 holders, $1.4m17 holders, $10.4bn
Q4 20251 holders, $2.9m19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
RGNX

Regenxbio Inc

Holders
2
Reported value
$2.1m
Buyers
1
Sellers
0

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
21
Reported value
$8.8bn
Buyers
16
Sellers
5

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only RGNX (2)

Moore Capital Management LP, Winton Group Ltd

Only AMGN (21)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →